Mana.bio

The Problem Mana.bio Addresses

Genetic medicines and RNA-based therapeutics have enormous potential to treat diseases that were previously considered undruggable. However, the effectiveness of these therapies depends heavily on the delivery system used to transport the fragile genetic material into cells. Naked RNA and DNA molecules are quickly degraded in the body and cannot easily cross cell membranes.

Lipid nanoparticles have emerged as the leading delivery platform, most famously demonstrated by their use in mRNA COVID-19 vaccines. Despite their success, designing LNPs remains a complex and largely trial-and-error process. Key challenges include:

• Achieving targeted delivery to specific organs or cell types beyond the liver, which LNPs naturally tend to accumulate in
• Optimizing the balance of lipid components for stability, potency, and tolerability
• Reducing the enormous experimental cost and time required to screen thousands of possible formulations
• Minimizing toxicity and immunogenicity while maximizing therapeutic effect

Mana.bio's core mission is to make the process of engineering these delivery systems faster, more rational, and more predictable through computational design.

What the Company Does

Mana.bio has developed an integrated platform that merges machine learning models with high-throughput laboratory experimentation. The company generates its own proprietary experimental data, feeding it back into predictive algorithms in an iterative "design-build-test-learn" cycle. This closed-loop approach allows the platform to continuously improve its ability to predict how a given lipid nanoparticle composition will behave.

Rather than relying solely on established chemistries, the company explores vast chemical and formulation spaces computationally, identifying promising candidates before committing to costly lab synthesis and testing. This dramatically narrows down the number of formulations that need to be physically produced and evaluated.

The central goal is tissue-specific and cell-specific targeting. While the liver is a relatively straightforward destination for LNPs, delivering payloads to other tissues such as the lungs, spleen, muscle, immune cells, or the central nervous system is far more difficult. Mana.bio's technology is oriented toward expanding the range of tissues that can be reliably reached, which would open the door to treating a much broader set of diseases.

Platform and Technology

The company's platform is built around several interconnected capabilities:

Computational and AI-driven design: Mana.bio uses machine learning models trained on both public data and its own generated datasets to predict the properties and performance of candidate lipid nanoparticle formulations. These models help prioritize which formulations are most likely to succeed.

High-throughput experimentation: The company runs automated laboratory workflows to synthesize, formulate, and test large numbers of nanoparticle candidates. This experimental engine produces the high-quality, standardized data needed to train and refine the AI models.

Iterative feedback loop: Experimental results are continuously fed back into the computational models, improving prediction accuracy over successive cycles. This integration of dry-lab and wet-lab work is a defining characteristic of the company's approach.

Payload flexibility: The platform is designed to support delivery of multiple types of therapeutic cargo, including mRNA, siRNA, and other nucleic acids, making it applicable across many therapeutic areas.

Products and Services

Mana.bio positions itself as a technology and platform company that can both develop its own delivery solutions and partner with others in the pharmaceutical and biotechnology industry. Its offerings center on:

Optimized lipid nanoparticle formulations: Custom-designed LNPs engineered for specific delivery objectives, such as targeting particular tissues or improving potency and tolerability.

Delivery technology development: Application of the company's AI-driven design engine to develop novel delivery systems tailored to a partner's therapeutic program or payload.

Collaborative partnerships: Mana.bio works with pharmaceutical and biotech organizations that have therapeutic payloads but require an effective and targeted delivery vehicle. Through these collaborations, the company applies its platform to accelerate the delivery portion of a partner's drug development pipeline.

Data-driven screening and optimization: Rather than offering purely off-the-shelf products, the company provides a rational, computationally guided process for arriving at improved delivery candidates faster than traditional trial-and-error methods.

Applications and Therapeutic Areas

Because lipid nanoparticles are a versatile delivery platform, the potential applications of Mana.bio's technology span a wide range of medical fields. These include:

• Vaccines based on mRNA technology
• RNA therapeutics for genetic and rare diseases
• Gene editing and gene silencing approaches
• Immunotherapies and treatments requiring delivery to immune cells
• Therapies targeting organs beyond the liver, where delivery has historically been limited

By improving the precision and efficiency of delivery, the company's work has the potential to unlock new treatment options across oncology, infectious disease, genetic disorders, and other areas.

Significance and Value Proposition

The value that Mana.bio brings to the life sciences industry lies in its ability to accelerate and de-risk one of the hardest parts of developing genetic medicines. Traditional LNP development is slow, expensive, and heavily dependent on empirical experimentation. By introducing predictive computational models grounded in real experimental data, the company aims to:

• Reduce the time required to identify effective delivery formulations
• Lower the cost of screening large numbers of candidates
• Expand the range of tissues and cell types that can be therapeutically targeted
• Improve the safety and efficacy profile of delivered therapeutics

This positions the company as an enabling technology provider within the broader movement toward RNA and genetic medicine, an area of intense research and commercial interest worldwide.

Conclusion

Mana.bio represents a modern approach to drug delivery innovation, one that treats the design of lipid nanoparticles as a computational and data science problem rather than a purely experimental one. By tightly integrating machine learning with high-throughput laboratory work, the company seeks to overcome longstanding barriers in targeted delivery of genetic medicines. Its platform and partnership-oriented model are aimed at helping the pharmaceutical and biotechnology industries bring more effective RNA-based and nucleic acid therapies to patients, potentially expanding what these powerful new classes of medicine can achieve.